NCT04251130View on ClinicalTrials.gov

Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI

Active, not recruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

March 11, 2020

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Mild Cognitive Impairment
Interventions
DRUG

2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine

A small molecule aimed for binding and PET-imaging of aggregated tau protein in the human brain.

Trial Locations (1)

19104

University of Pennsylvania, School of Medicine, Philadelphia

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of Pennsylvania

OTHER